(VIANEWS) – The NASDAQ ended the session with TherapeuticsMD rising 18.5% to $2.69 on Tuesday, after two sequential sessions in a row of losses. NASDAQ rose 1.13% to $14,284.53, after four sequential sessions in a row of gains, on what was an all-around positive trend exchanging session today.
TherapeuticsMD’s last close was $2.27, 68.38% below its 52-week high of $7.18.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, TherapeuticsMD has a trailing twelve months EPS of $3.41.
PE Ratio
TherapeuticsMD has a trailing twelve months price to earnings ratio of 0.79. Meaning, the purchaser of the share is investing $0.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1134.2%.
More news about TherapeuticsMD (TXMD).
